한글목차

세계의 펜플루리돌 시장 전망은 병원, 클리닉, 약국 시장에서의 기회가 있고 유망시되고 있습니다. 세계의 펜플루리돌 시장은 2025-2031년에 걸쳐 CAGR 2.1%로 성장할 전망입니다. 이 시장의 주요 촉진 요인은 만성 정신분열증 환자의 증가, 장기 항정신병 약물에 대한 수요 증가, 정신 건강 치료에 대한 관심 증대입니다.

• Lucintel의 예측은 유형별로 정제 형태가 예측 기간 동안 가장 높은 성장률을 기록할 것으로 예상됩니다.
• 용도별로 병원이 가장 높은 성장률을 기록할 것으로 예상됩니다.
• 지역별로 아시아태평양이 예측 기간 동안 가장 높은 성장이 예상됩니다.

150페이지 이상의 종합적인 보고서를 통해 비즈니스 의사 결정에 도움이 되는 유용한 인사이트를 얻을 수 있습니다.

펜플루리돌 시장의 새로운 동향

펜플루리돌 시장은 항정신병 약물로 사용되는 전통적인 용도를 외에는 다양한 신흥 동향의 영향을 받고 있습니다. 이러한 동향은 연구에서 새로운 발견, 특히 의약품 재사용 분야에서의 성과, 그리고 정신 건강 치료에서 효과적이고 편리한 장기 작용 치료 솔루션에 대한 지속적인 수요에 의해 촉진되고 있습니다.

• 암 의약품 시장에서의 약물 재사용 : 펜플루리돌의 암 치료제 재사용에 대한 강력한 증가세가 관찰되고 있습니다. 연구 결과, 유방암, 췌장암, 뇌종양 등 다양한 암 세포 라인에서 서로 다른 메커니즘을 통해 항종양 활성을 보여 새로운 항암 의약품 후보로 주목받고 있습니다.
• 나노입자 기반 약물 전달 시스템 : 펜플루리돌을 위한 나노입자 기반 약물 전달 시스템이 연구 중입니다. 이는 생체 이용률을 높이고 표적 전달을 용이하게 하며, 특히 기존 제형이 효과적이지 않은 난치성 사례에서 용도를 확장할 수 있는 가능성을 모색하는 동향입니다.
• 경구용 장기 작용형 복용 준수 초점 : 주 1회 투여 요법을 가진 경구용 장기 작용형 항정신병 약물로서 펜플루리돌은 특히 주사제 장기 작용형 제제를 거부하는 환자들에서 환자 복약 순응도를 향상시키는 능력으로 인해 주목받고 있습니다.
• API 생산 및 수출 성장 : 전 세계적으로 비용 효율적이고 신뢰할 수 있는 장기 작용 경구용 항정신병제에 대한 수요 증가로 인해, 특히 인도와 중국 등 국가에서 펜플루리돌 활성 의약품(API)의 생산 및 수출이 크게 증가하는 동향입니다.
• 지적 재산권 및 바이오시밀러 활동 : 펜플루리돌 전구체에 대한 특허 출원 증가세는 지속적인 연구 개발 투자를 반영합니다. 이는 주요 특허가 만료됨에 따라 바이오시밀러 또는 제네릭 경쟁이 발생할 가능성이 있으며, 이는 시장 동향과 접근성에 영향을 미칠 것입니다.

이러한 동향은 펜플루리돌 시장을 재정의하고 있으며, 기존의 항정신병 약물 역할 외에 특히 종양학 분야로 치료 용도가 크게 확대되다. 새로운 투여 메커니즘, 경구 복용 순응도 향상, 전 세계 API 제조, 지적 재산권 활동에 대한 강조는 이 성숙한 의약품에 대한 새로운 기회를 제공하는 활기찬 미래를 예고합니다.

펜플루리돌 시장의 최근 동향

성숙한 시장임에도 불구하고 펜플루리돌 시장은 최근 몇 가지 트렌드로 인해 적용 범위와 미래 잠재력에 영향을 받고 있습니다. 이러한 트렌드는 주로 새로운 치료 용도 연구, 특히 암 분야에서의 연구와 국제 제약 생산 및 유통 변화에 의해 영향을 받고 있습니다.

• 항암 활성 발견 : 펜플루리돌의 다양한 암 세포 라인에서 강력한 항종양 활성이 발견된 것은 의약품의 종양학 분야 재사용에 대한 연구 관심을 높이고 있습니다.
• API 생산 증가 : 펜플루리돌 활성 유효 성분(API) 제조 및 수출이 인도와 중국을 중심으로 국제 제네릭 시장을 타겟팅하여 눈에 띄게 증가했으며, 이는 접근성을 높이고 있습니다.
• 나노입자 전달 연구 : 현재 연구는 펜플루리돌의 효능을 향상시키고 난치성 질환에서의 새로운 용도를 탐색하기 위해 나노입자 기반 전달 시스템을 개발하는 데 초점을 두고 있습니다.
• 전구체 약물 특허 출원 : 최근 몇 년간 펜플루리돌 전구체 약물의 특허 출원이 증가한 것은 약리학적 특성을 개선하고 시장 독점권을 확보하기 위한 지속적인 연구 개발 투자를 반영합니다.
• 치료 저항성 정신분열증에서의 역할 : 일부 시장에서 임상 및 실제 세계 증거는 펜플루리돌이 치료 저항성 정신분열증 환자군에서 효과적임을 뒷받침하며, 이 특정 적응증에 대한 수요를 확대되고 있습니다.

이들은 펜플루리돌 시장에게 역사적인 항정신병 약물로서의 암 치료 용도를 외에 새로운 잠재적 치료 용도를 열어주는 결정적인 진전입니다. API 제조, 전달 기술, 지적 재산권 분야의 혁신은 펜플루리돌에 대한 새로운 활동을 시사하며, 특정 틈새 시장에서 이 약물의 더 넓은 수용과 시장 진출을 촉진할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계의 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 펜플루리돌 시장 : 유형별

• 개요
• 유형별 매력 분석
• 정제 : 동향과 예측(2019-2031년)
• 캡슐 : 동향과 예측(2019-2031년)

제5장 세계의 펜플루리돌 시장 : 용도별

• 개요
• 용도별 매력 분석
• 병원 : 동향과 예측(2019-2031년)
• 클리닉 : 동향과 예측(2019-2031년)
• 약국 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역별 펜플루리돌 세계의 시장

제7장 북미의 펜플루리돌 시장

• 개요
• 북미의 펜플루리돌 시장(유형별)
• 북미의 펜플루리돌 시장(용도별)
• 미국의 펜플루리돌 시장
• 멕시코의 펜플루리돌 시장
• 캐나다의 펜플루리돌 시장

제8장 유럽의 펜플루리돌 시장

• 개요
• 유럽의 펜플루리돌 시장(유형별)
• 유럽의 펜플루리돌 시장(용도별)
• 독일의 펜플루리돌 시장
• 프랑스의 펜플루리돌 시장
• 스페인의 펜플루리돌 시장
• 이탈리아의 펜플루리돌 시장
• 영국의 펜플루리돌 시장

제9장 아시아태평양의 펜플루리돌 시장

• 개요
• 아시아태평양의 펜플루리돌 시장(유형별)
• 아시아태평양의 펜플루리돌 시장(용도별)
• 일본의 펜플루리돌 시장
• 인도의 펜플루리돌 시장
• 중국의 펜플루리돌 시장
• 한국의 펜플루리돌 시장
• 인도네시아의 펜플루리돌 시장

제10장 기타 지역의 펜플루리돌 시장

• 개요
• 기타 지역의 펜플루리돌 시장(유형별)
• 기타 지역의 펜플루리돌 시장(용도별)
• 중동의 펜플루리돌 시장
• 남미의 펜플루리돌 시장
• 아프리카의 펜플루리돌 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 세계의 펜플루리돌 시장에서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴, 합작 사업

제13장 밸류체인에서 주요 기업의 기업 프로파일

• 경쟁 분석
• Hunan Dongting Pharm
• Jiangsu Nhwa Pharmaceutical
• Sphsine Pharm
• Chongqing Qingyang Pharmaceutical
• Kamp
• Harbin Pharmaceutical Group
• Fuhe Group
• Hunan Zhongnan Pharm
• Lifecare Neuro Products
• Enomark

제14장 부록

• 참조문헌 목록
• 참조 표 목록
• 연구 방법론
• 면책 조항
• 저작권
• 약어 및 기술 단위
• 회사 소개
• 문의처

영문목차

The future of the global penfluridol market looks promising with opportunities in the hospital, clinic, and pharmacy markets. The global penfluridol market is expected to grow with a CAGR of 2.1% from 2025 to 2031. The major drivers for this market are the increasing cases of chronic schizophrenia, the rising demand for long-term antipsychotics, and the growing focus on mental health treatment.

• Lucintel forecasts that, within the type category, tablets are expected to witness higher growth over the forecast period.
• Within the application category, hospitals are expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Penfluridol Market

The market for penfluridol is affected by a number of emerging trends that reach beyond its classic application as an antipsychotic. They are fueled by new discoveries from research, more specifically in drug repurposing, and the constant demand for effective and easy long-acting treatment solutions in mental health treatment.

• Drug Repurposing in Oncology: There is a robust upsurge in the repurposing of penfluridol in cancer therapies. Studies point to its anti-tumor activity in a range of cancer cell lines such as breast, pancreatic, and glioblastoma via differing mechanisms, making it a candidate for a new anti-cancer drug.
• Nanoparticle-Based Delivery Systems: Nanoparticle-based delivery systems are being researched for penfluridol. This is a trend that seeks to increase its bioavailability, facilitate targeted delivery, and possibly extend its uses, especially in refractory cases where conventional formulations are less effective.
• Oral Long-Acting Adherence Focus: Penfluridol's status as an oral long-acting antipsychotic with a weekly dosing regimen is receiving increased interest for its ability to enhance patient compliance, particularly for those patients who refuse injectable long-acting preparations.
• API Production and Export Growth: There is a significant trend towards the growth of penfluridol active pharmaceutical ingredient (API) production and export, particularly from nations such as India and China, due to worldwide demand for cost-efficient and dependable long-acting oral antipsychotics.
• Intellectual Property and Biosimilar Activity: The upswing in filings on patents for penfluridol prodrugs reflects continued research and development investment. This implies a future trend of potential biosimilar or generic competition as major patents mature, impacting market dynamics and access.

These trends are collectively redefining the penfluridol market by vastly expanding its therapeutic application beyond its conventional antipsychotic role, especially into oncology. The emphasis on new delivery mechanisms, enhancing oral compliance, worldwide API manufacturing, and intellectual property activity indicates a vibrant landscape with fresh opportunities for this mature drug.

Recent Developments in the Penfluridol Market

The penfluridol market, though mature, is facing some recent trends that are affecting its application and potential future. These trends are mostly influenced by upcoming research into novel therapeutic uses, especially in oncology, and changes in international pharmaceutical production and distribution.

• Anticancer Activity Discovery: One key development is the discovery of penfluridol's potent anti-tumor activities in different cancer cell lines, which has generated growing research interest in the oncology repurposing of drugs.
• Growth in API Production: There has been appreciable growth in penfluridol active pharmaceutical ingredient (API) manufacturing and exportation, especially from India and China, targeting international generic markets and raising accessibility.
• Nanoparticle Delivery Research: Current research is aimed at creating nanoparticle-based delivery systems for penfluridol with the hope of increasing its efficacy and possibly finding new uses for it in refractory conditions.
• Patent Filings for Prodrugs: An increase in patent filings for penfluridol prodrugs over the past few years reflects continued research and development spending, indicating an interest in enhancing its pharmacological characteristics and providing market exclusivity.
• Role in Treatment-Resistant Schizophrenia: Clinical and real-world evidence in a few markets are underpinning penfluridol's effectiveness in a niche of treatment-resistant schizophrenia patients, expanding demand for this particular indication.

These are pivotal advancements that are strongly influencing the penfluridol market by opening new potential therapeutic applications beyond its historic antipsychotic use in oncology. The innovation of API manufacturing, delivery technologies, and intellectual property suggests renewed activity in penfluridol, possibly sparking its wider acceptance and market appearance in certain niches.

Strategic Growth Opportunities in the Penfluridol Market

The penfluridol market, though mostly recognized for its antipsychotic activity, offers strategic growth opportunities through the discovery and development of its potential in new therapeutic uses. Targeting these new areas can unlock tremendous market growth and reposition the drug beyond its existing main use.

• Targeting Treatment-Resistant Cancers: The development of penfluridol as a new therapeutic compound for treatment-resistant cancers, especially those where it has been demonstrated to have substantial anti-tumor effects such as glioblastoma and triple-negative breast cancer, is a significant opportunity for growth.
• Adjunctive Therapy in Oncology: Exploration of penfluridol as an adjunctive therapy to augment the effectiveness of current chemotherapy or immunotherapy regimens in cancer therapy based on its synergistic anti-tumor actions.
• Managing Schizophrenia Non-Adherence: Highlighting penfluridol's benefit as an oral long-acting antipsychotic for patients with poor compliance to daily oral medication or those who reject injectable long-acting formulations, offering a convenient option.
• Behavioral Symptoms in Dementia: Investigating and clinically confirming penfluridol's potential in the management of severe behavioral and psychological symptoms of dementia, where its long-acting oral profile may provide advantages for patient and caregiver convenience.
• New Drug Delivery for Refractory Cases: Formulating new drug delivery systems, including nanoparticle formulations, to enhance the bioavailability and targeted delivery of penfluridol for refractory cases in both its historic antipsychotic and future cancer uses.

These application-based strategic growth opportunities are affecting the penfluridol market by radically transforming its scope from conventional psychiatric applications, with a dominant focus on oncology. The investigation into adjunctive therapy, niche applications in mental health, and new delivery systems reflects an earnest attempt to take penfluridol's therapeutic value to the maximum and increase its market reach.

Penfluridol Market Driver and Challenges

The penfluridol market is affected by a distinctive combination of factors that are both major drivers for its application and significant challenges for its expansion and extensive usage. They are its pharmacological profile, economic factors, and advancing scientific findings that are reformulating its perceived value and potential.

The factors responsible for driving the penfluridol market include:

1. Long-Acting Oral Administration: An important impetus is penfluridol's long-acting oral pharmacokinetic profile, making it possible to administer once a week, significantly enhancing patient compliance to long-term medication treatment in conditions such as schizophrenia.

2. Cost-Effectiveness: Penfluridol tends to be cheaper than newer, patented long-acting injectable antipsychotics and thus becomes a cost-saving option in cost-conscious healthcare systems and for poorer patients.

3. Repurposing in Oncology: The newly emerging evidence of penfluridol's strong anti-tumor activity across different cancer cell lines has emerged as a prime driver, possibly broadening its therapeutic indications and opening up new market opportunities.

4. Established Efficacy in Schizophrenia: Although an older antipsychotic, penfluridol has established efficacy in the treatment of the positive symptoms of schizophrenia, especially for maintenance therapy, supporting its ongoing use in some clinical contexts.

5. API Production and Export: The strong active pharmaceutical ingredient (API) manufacturing base, particularly in India and China, provides a stable and low-cost supply, fueling its presence in international generic markets.

Challenges in the penfluridol market are:

1. Limited US and European Approval: Penfluridol lacks broad approval and commercialization in the US and some parts of Europe for its antipsychotic application, restricting its market penetration and recognition in these key pharmaceutical markets.

2. Newer Antipsychotics Competition: The product is subject to strong competition from newer, more extensively marketed atypical antipsychotics, particularly long-acting injectables, which tend to have a wider range of indications and a more acceptable side effect profile.

3. Side Effect Profile: As with other first-generation antipsychotics, penfluridol can be linked with extrapyramidal side effects, which can affect patient tolerability and adherence, presenting a barrier to its wider use.

The principal drivers of its long-acting oral profile, cost benefit, and new oncology uses are maintaining and potentially enhancing the penfluridol business. While challenges of its limited approval in major markets, competition from more recently approved drugs, and its side effect profile create the need for continued research and strategic positioning to maintain its relevance and therapeutic value.

List of Penfluridol Companies

• Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, penfluridol companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the penfluridol companies profiled in this report include:
• Hunan Dongting Pharm
• Jiangsu Nhwa Pharmaceutical
• Sphsine Pharm
• Chongqing Qingyang Pharmaceutical
• Kamp
• Harbin Pharmaceutical Group
• Fuhe Group
• Hunan Zhongnan Pharm
• Lifecare Neuro Products
• Enomark

Penfluridol Market by Segment

The study includes a forecast for the global penfluridol market by type, application, and region.

Penfluridol Market by Type [Value from 2019 to 2031]:

• Tablets
• Capsules

Penfluridol Market by Application [Value from 2019 to 2031]:

• Hospital
• Clinic
• Pharmacy
• Others

Penfluridol Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Penfluridol Market

The penfluridol market, although niche, is witnessing changing dynamics with its novel long-acting oral profile for schizophrenia treatment and growing research into new therapeutic uses. Recent trends indicate regional differences in clinical practice, regulatory environments, and increased interest in drug repurposing. These trends are affecting manufacturing, distribution, and future potential of penfluridol.

• United States: Penfluridol is not commonly approved or sold in the US. Current activity is mostly focused on the investigation of its repurposing potential in oncology, rather than on its original antipsychotic indication. The US market continues to be dominated by newer, long-acting injectables for schizophrenia.
• China: China is a large producer and consumer of penfluridol, mainly for the treatment of schizophrenia. Recent news has involved regulatory approvals of new generic versions to expand availability and attempts by local producers to fulfill rising demand. In addition, research on the anti-tumor property of penfluridol has been conducted.
• Germany: Penfluridol's presence in Germany is limited among other antipsychotics. Current trends emphasize its application to particular clinical niches in the case of treatment-resistant patients who have poor compliance with daily oral medication, sometimes based on clinical experience over years. Emphasis remains on more recently introduced and more commonly prescribed antipsychotics.
• India: India is a key world supplier of penfluridol API and finished products, especially generic ones. Developments in recent times include the expansion of production capacity to satisfy international demand for its API and expanded domestic utilization, fueled by its cost-effectiveness and long-acting oral profile for schizophrenia treatment.
• Japan: Penfluridol is represented in Japan with a special emphasis upon its long-lasting oral efficacy. New trends comprise continued clinical practice with its usage in schizophrenia as well as growth in interest within its use within the control of behavioral disturbances associated with dementia in line with a population in increased age.

Features of the Global Penfluridol Market

• Market Size Estimates: Penfluridol market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Penfluridol market size by type, application, and region in terms of value ($B).
• Regional Analysis: Penfluridol market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the penfluridol market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the penfluridol market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the penfluridol market by type (tablets and capsules), application (hospital, clinic, pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Penfluridol Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Tablets: Trends and Forecast (2019-2031)
• 4.4 Capsules: Trends and Forecast (2019-2031)

5. Global Penfluridol Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital: Trends and Forecast (2019-2031)
• 5.4 Clinic: Trends and Forecast (2019-2031)
• 5.5 Pharmacy: Trends and Forecast (2019-2031)
• 5.6 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Penfluridol Market by Region

7. North American Penfluridol Market

• 7.1 Overview
• 7.2 North American Penfluridol Market by Type
• 7.3 North American Penfluridol Market by Application
• 7.4 United States Penfluridol Market
• 7.5 Mexican Penfluridol Market
• 7.6 Canadian Penfluridol Market

8. European Penfluridol Market

• 8.1 Overview
• 8.2 European Penfluridol Market by Type
• 8.3 European Penfluridol Market by Application
• 8.4 German Penfluridol Market
• 8.5 French Penfluridol Market
• 8.6 Spanish Penfluridol Market
• 8.7 Italian Penfluridol Market
• 8.8 United Kingdom Penfluridol Market

9. APAC Penfluridol Market

• 9.1 Overview
• 9.2 APAC Penfluridol Market by Type
• 9.3 APAC Penfluridol Market by Application
• 9.4 Japanese Penfluridol Market
• 9.5 Indian Penfluridol Market
• 9.6 Chinese Penfluridol Market
• 9.7 South Korean Penfluridol Market
• 9.8 Indonesian Penfluridol Market

10. ROW Penfluridol Market

• 10.1 Overview
• 10.2 ROW Penfluridol Market by Type
• 10.3 ROW Penfluridol Market by Application
• 10.4 Middle Eastern Penfluridol Market
• 10.5 South American Penfluridol Market
• 10.6 African Penfluridol Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Penfluridol Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Hunan Dongting Pharm
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Jiangsu Nhwa Pharmaceutical
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Sphsine Pharm
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Chongqing Qingyang Pharmaceutical
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Kamp
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Harbin Pharmaceutical Group
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Fuhe Group
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Hunan Zhongnan Pharm
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Lifecare Neuro Products
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Enomark
  • Company Overview
  • Penfluridol Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us